Unless specifically stated in the program announcement, standard due dates
for competing applications apply.
Please see http://grants.nih.gov/grants/funding/submissionschedule.htm
for complete listing of cycle due dates as well as review and award cycles.
The National Cancer Institute does NOT accept R21 or R03 funding mechanism
proposals for the Parent Program Announcements.
Parent Program Announcements
Research Project Grant (Parent R01)
Program Announcement: PA-07-070
Due Date: Standard Due Dates Apply
Program Expires: January 8, 2010
-
Purpose: The Research Project Grant (R01) is an award made to
an institution/organization to support a discrete, specified, circumscribed
project to be performed by the named investigator(s) in areas representing the
specific interests and competencies of the investigator(s). The R01 research
plan proposed by the applicant institution/organization must be related to the
stated program interests of one or more of the NIH Institutes and Centers (ICs)
based on descriptions of their programs. All research project grant
applications described in this announcement will be assigned to NIH ICs
according to standard Public Health Service (PHS) referral guidelines and
specific program interests. Investigators are encouraged to consult the
participating NIH ICs and their Web sites (see http://www.nih.gov/icd).
-
Mechanism of Support-
This FOA will utilize the R01 award mechanism
-
Budget and Project Period-
The total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See:
http://grants.nih.gov/grants/guide/pa-files/PA-07-070.html for
instructions and participating institutes.
NIH Exploratory/Developmental Research Grant Program (Parent
R21)
Program Announcement: PA-06-181
Due Date: Standard Due Dates Apply
Program Expires: May 8, 2009
-
Purpose:
The R21 mechanism is intended to encourage new exploratory and developmental
research projects. For example, such projects could assess the feasibility of a
novel area of investigation or a new experimental system that has the potential
to enhance health-related research. Another example could include the unique
and innovative use of an existing methodology to explore a new scientific area.
These studies may involve considerable risk but may lead to a breakthrough in a
particular area, or to the development of novel techniques, agents,
methodologies, models, or applications that could have a major impact on a
field of biomedical, behavioral, or clinical research.
-
Mechanism of Support:
This FOA utilizes the Exploratory/Developmental grant (R21) mechanism.
-
Budget and Project Period:
The total project period may not exceed 2 years. Direct costs are limited to
$275,000 over a 2-year period, with no more than $200,000 in direct costs
allowed in any single year.
-
See:
http://grants.nih.gov/grants/guide/pa-files/PA-06-181.html for
instructions and participating institutes.
NIH Small Research Grant Program (Parent R03)
Program Announcement: PA-06-180
Due Dates: Standard Due Dates Apply
Program Expires: May 8, 2009
-
Purpose:
The National Institutes of Health (NIH) Investigator-Initiated Small Grant
(R03) funding opportunity supports small research projects that can be carried
out in a short period of time with limited resources. Investigator-initiated
research, also known as unsolicited research, is research funded as a result of
an investigator submitting a research grant application to NIH in an
investigator’s area of interest and competency. The R03 grant mechanism
supports different types of projects including pilot and feasibility studies;
secondary analysis of existing data; small, self-contained research projects;
development of research methodology; and development of new research
technology.
-
Mechanism of Support:
This funding opportunity will use the NIH Small Research Grant (R03) award
mechanism
-
Budget and Project Period:
A project period of up to two years and a budget for direct costs of up to two
$25,000 modules or $50,000 per year may be requested.
-
See:
http://grants.nih.gov/grants/guide/pa-files/PA-06-180.html for
instructions and participating institutes.
Basic and Clinical Studies of Congenital Urinary Tract
Obstruction (R01)
Program Announcement: PA-07-059
Participating Institute- NIDDK
Due Date: Standard Due Dates Apply
Expires May 8, 2009
-
Purpose:
Congenital obstructive uropathy is one of the major causes of chronic kidney
disease and end stage renal disease (ESRD) in infants and children. The
pathogenesis of this disorder, however, remains poorly understood. Many
controversies and clinical uncertainties exist in the detection, prognosis, and
effective treatment strategies for this condition. The impact of early fetal
detection and neonatal intervention, the long-term effects of watchful waiting
and the various surgical interventions have not been well studied and
documented. There is also no consensus on the indications for, or ideal timing
of surgical intervention. The purpose of this funding opportunity is to address
the numerous scientific and clinical uncertainties related to the development,
treatment and prognosis of congenital obstructive uropathy, by encouraging and
facilitating research in diverse areas. These areas include: the development of
objective prognostic markers; the genetic determinants of this congenital
disorder; the development of reliable animal models of the disorder; and,
evaluation of the long-term effectiveness of various treatment strategies.
-
Mechanism of Support- This FOA will utilize the R01 award
mechanism.
-
Budget and Project Period- The total project may not
exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-059.html
for R01 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-06-162.html
for R21 FOA.
Studies of
Energy Balance and Cancer in Humans (R01)
Program Announcement: PA-07-176
Participating Institute- NCI
Due Date:Standard Due Dates Apply
Expires May 8, 2009
-
Purpose. This Funding Opportunity
Announcement (FOA) invites grant applications for studies that focus on
research to define factors affecting energy balance and to define mechanisms
influencing cancer risk, prognosis, and quality of life. These studies may
range from new analyses of existing datasets to additional collection of data
and biological specimens in ongoing investigations. It is anticipated that the
knowledge gained will provide additional information to better understand the
relationships among energy balance, cancer risk, and prognosis.
-
Mechanism of Support- This FOA
will utilize the R01 grant mechanism.
-
Budget and Project Period- The
total project may not exceed 5 years.
-
-
-
Phased Innovation Research in Cancer Prognosis and
Prediction (R21/R33)
Program Announcement: PA-06-434
Participating Institute-NCI
Due Date:
Standard Due Dates Apply
Expires May 8, 2009
-
Purpose. This funding opportunity announcement (FOA)
solicits Phased grant applications from applicant organizations that propose
research projects to evaluate the utility and pilot the application of new
strategies for determining prognosis or predicting response to therapy. This
program will provide tools to improve clinical decision-making in the care of
cancer patients. This FOA provides support for a first phase (R21) for initial
technical development and proof-of-principle, and a second phase (R33) for
further development, application, and evaluation of clinical utility. The first
phase should produce data to demonstrate the technical feasibility of the study
design proposed for the second phase, including the analytic performance of the
assay or test system on samples comparable to those that will be used in the
second phase. The second phase should be designed to test whether application
of the strategy will provide clinical benefit to a defined set of cancer
patients.
-
Mechanism of Support- This FOA will utilize the NIH Phased
Innovation (combined R21 [Phase I, Exploratory]/R33 [Phase II, Developmental])
grant mechanism.
-
Budget and Project Period- The total project period may
not exceed 5 years. Direct costs are limited to $275,000 over an initial R21
2-year period, with no more than $200,000 in direct costs allowed in any single
year. There are no direct cost limits on the R33 phase.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-06-434.html
for R01 FOA.
Phase II Developmental Research in Cancer Prognosis and
Prediction (R33)
Program Announcement: PA-06-435
Participating Institute-NCI
Due Date:
Standard Due Dates Apply
Expires May 8, 2009
-
Purpose. This funding opportunity announcement (FOA)
solicits R33 grant applications from applicant organizations that propose
research projects to evaluate the utility and pilot the application of new
strategies for determining prognosis or predicting response to therapy. This
program will provide tools to improve clinical decision-making in the care of
cancer patients. The proposed project should be designed to test whether
application of the strategy will provide clinical benefit to a defined set of
cancer patients.
-
Mechanism of Support- This FOA will utilize the NIH R33 (Phase
II, Developmental) grant mechanism and it runs in parallel with a FOA of
identical scientific scope,
PA-06-434, that solicits applications using the NIH R21/R33 (Phased
Application) grant mechanism. The anticipated number of awards is about
four.
-
Budget and Project Period- The total project period for an
application submitted in response to this FOA may not exceed 4 years. There are
no direct cost limits.
-
Special Instructions for Applications Requesting $500,000 (direct costs) or
More Per Year-see
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html
for a complete description of policy and requirements.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-06-435.html
for FOA.
Application of Metabolomics for Translational and Biological
Research (R01)
Program Announcement: PA-07-301
Participating Institutes-NCI
Due Date:
Standard Due Dates Apply
Expires January 3,
2010
-
Purpose. Metabolomics enables simultaneous
identification and analysis of multiple metabolites in cells, tissues and body
fluids. This Funding Opportunity Announcement (FOA) is an initiative
sponsored by several NIH institutes to promote the application of metabolomic
technologies for translational research in human health and disease to
enable/improve disease detection, diagnosis, risk assessment, prognosis, and
prediction of therapeutic responses.
-
Mechanism of Support:
This FOA uses the NIH Research Project Grant (R01) award mechanism.
-
Budget and Project Period:
The total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-301.html
for R01 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-302.html
for R21 FOA.
Endoscopic Clinical Research In Pancreatic And Biliary
Diseases (R03)
Program announcement: PAR-06-171
Participating Institutes-NIDDK/NCI
Due Date:
Standard Due Dates Apply
Expires
May 2, 2009
-
Purpose:
This funding opportunity will encourage clinical research in a number of
areas: Comparisons of interventional endoscopic procedures vs.
interventional radiological approaches vs. surgery for treatment of different
complications of chronic pancreatitis. Studies of the role of endoscopic
interventions for acute pancreatitis, chronic pancreatitits or its
complications. Studies of the role of ERCP in sphincter of Oddi
dysfunction (biliary or pancreatic sphincter). Clinical studies of early
detection and diagnosis, prognostication, prevention and treatment
of acute and chronic pancreatitis as well as pancreatic cancer. The
clinical significance, natural history, and management of microlithiasis or
"biliary sludge" in the pathogenesis of pancreatitis. Clinical
studies of the role of endoscopic and other advanced technologies in early
diagnosis, staging or treatment of biliary or pancreatic malignancy; including
but not limited to the collection of pancreatic juice for the chemical
analysis, cytopathology, proteomics, and gene expression microarrays. Other
studies of pancreatic and biliary diseases that compare ERCP, diagnostic
imaging or surgical approaches. Studies to enhance and evaluate training for
laparoscopic common bile duct exploration (and other surgical techniques) and
to improve training for advanced endoscopy. Development of endoscopic and
laparoscopic simulators and other new technologies to facilitate training,
maintenance and objective assessment of procedural performance.
-
Mechanism of Support:
This funding opportunity will use the NIH Small Research Grant (R03) award
mechanism
-
Budget and Project Period:
A project period of up to two years and a budget for direct costs of up to two
$25,000 modules or $50,000 per year may be requested.
-
See http://grants.nih.gov/grants/guide/pa-files/PAR-06-171.html
for FOA.
Chronic Illness Self-Management in Children and Adolescents
(R01)
Program Announcement: PA-07-097
Participating Institutes-NINR/NICHD/NIDDK/NCI/NHLBI/ODS
Due Date:
Standard Due Dates Apply
Expires January 3, 2010
-
Purpose:
to solicit research to improve self-management and quality of life in children
and adolescents with chronic illnesses. Biobehavioral studies of children
in the context of family and family-community dynamics are encouraged. Children
diagnosed with a chronic illness and their families have a long-term
responsibility for self-management. The child with the chronic illness will
have a life-long responsibility to maintain and promote health and prevent
complications. Research related to biological/ technological factors, as
well as, sociocultural, environmental, and behavioral mechanisms that
contribute to successful and ongoing self-management of chronic illnesses in
children is also encouraged. This FOA is restricted to studies of chronic
illnesses in children and adolescents ages 8 to 21 grouped by developmental
stages according to the discretion of the investigator. Studies of
chronic mental illness or serious cognitive disability are beyond the scope of
this FOA.
-
Mechanism of Support:
This FOA uses the NIH Research Project Grant (R01) award mechanism.
-
Budget and Project Period:
The total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See: http://grants.nih.gov/grants/guide/pa-files/PA-07-097.html
for R01 FOA.
-
See: http://grants.nih.gov/grants/guide/pa-files/PA-07-099.html
for R21 FOA.
-
See: http://grants.nih.gov/grants/guide/pa-files/PA-07-098.html
for R03 FOA.
HIV Infection Of The Central Nervous System (R01)
Program Announcement: PA-07-089
Participating Institutes-NIMH/NINDS/NIDA/NIAAA
Due Date: September 7, 2008
Expires September 8, 2010
-
Purpose:
The purpose of this Funding Opportunity Announcement (FOA) is to invite grant
applications to support research focused on determining the pathogenic
mechanisms involved in Human Immunodeficiency Virus (HIV)-1 associated
neurobehavioral and neurological dysfunction in domestic and international
settings. The objective of this cooperative effort is to foster
investigations that will provide the foundation for the rapid development of
therapeutic interventions to prevent and treat the effects of HIV-1 on the
central nervous system (CNS). Applications ranging from basic research to
clinical diagnosis and treatment are of interest. Multidisciplinary
research teams and collaborative alliances are encouraged but not required.
-
Mechanism of Support:
This FOA utilizes the NIH Research Project Grant (R01) award mechanisms.
-
Budget and Project Period:
The total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See: http://grants.nih.gov/grants/guide/pa-files/PA-07-089.html
for R01 FOA.
Building Translational Research in Integrative Behavioral
Science (R01)
Program Announcement: PAR-07-155
Participating Institutes-NIMH/NINDS/NIDA/NIAAA
Due Date: Standard Due Dates Apply
Due Date: January 25, 2009- R24
Expires May 8, 20009 -R21, R24
Expires March 6, 2009- R01
-
Purpose: This Funding Opportunity Announcement (FOA) is
intended to encourage the development of collaborative partnerships between
scientists who study basic behavioral processes and those who study the
etiology, diagnosis, treatment, and prevention of mental and behavioral
disorders (including drug abuse and addiction) and the delivery of services to
those suffering from those disorders. The National Institute of Mental
Health (NIMH) and the National Institute on Drug Abuse (NIDA), National
Institutes of Health (NIH), are issuing this FOA as part of a major, long-term
commitment to (a) encourage the systematic translation of basic behavioral
theory, methods, and findings into research designed to reduce the burden of
mental illness and behavioral disorders (including drug abuse and addiction)
and (b) encourage basic behavioral scientists to seek a further understanding
of behavioral processes through an exploration of how those processes are
altered by mental and behavioral disorders. This FOA was developed in
response to a report written by the National Advisory Mental Health Council's
Behavioral Science Workgroup, entitled "Translating Behavioral Science into
Action," http://www.nimh.nih.gov/tbsia/tbsiatoc.cfm.
-
Mechanism of Support:
This funding opportunity will use the R01 mechanism.
-
Budget and Project Period:
The total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See: http://grants.nih.gov/grants/guide/pa-files/PAR-07-155.html
for R01 FOA.
-
See: http://grants.nih.gov/grants/guide/pa-files/PAR-06-357.html
for R24 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PAR-06-355.html
for R21 FOA
Mental Health Consequences Of Violence And Trauma (R01)
Program Announcement: PA-07-312
Participating Institute-NIMH
Due Date: Standard Due Dates Apply
Expires November 6, 2009- R01
Expires November 17, 2009- R03, R21, R34
-
Purpose:
The National Institute of Mental Health (NIMH) invites research grant
applications for investigator-initiated research to enhance scientific
understanding of the etiology of psychopathology related to violence and
trauma, as well as studies to develop and test effective treatments, services,
and prevention strategies in this area. Areas of particular interest to
the NIMH include interdisciplinary approaches combining multiple levels of
inquiry (e.g., psychological, neurobiological, genetic) and scientific tools
(e.g., ecological assessment, neuroimaging, microarrays) for psychopathology
risk modeling, identification of highly predictive markers of pathology, and
improved diagnostics; translation of basic behavioral and neuroscience findings
on resiliency and risk for intervention development and testing; and strategies
for effective service provision, particularly where non-specialty systems
(i.e., primary care) may be required to provide mental health services.
-
Mechanism of Support:
FOA utilizes the NIH Research Project Grant (R01) award mechanism.
-
Budget and Project Period:
The total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-312.html
for R01 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-314.html
for R21 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-313.html
for R03 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PAR-07-315.html
for R34 FOA.
Pilot And Feasibility Clinical Research Grants In Kidney Or
Urologic Diseases (R21)
Program Announcement: PAR-06-113
Participating Institute-NIDDK
Due Date: Standard Due Dates Apply
Expires January 3, 2009
-
Purpose:
This funding opportunity (FOA) encourages the submission of applications for
pilot and feasibility clinical and translational research studies, including
clinical trials, and epidemiological studies, related to kidney or urologic
disease research that address important clinical and translational questions
and are potentially of high impact. It is anticipated that applications for
pilot and feasibility studies may lead to full-scale clinical studies including
diagnostic strategies, epidemiologic studies, or trials in the diagnosis,
prevention, pre-emption, or treatment of kidney or urologic disease.
-
Mechanism of Support:
This FOA will use the R21 award mechanism.
-
Budget and Project Period:
The applicant may request a project period of up to 2 years with a combined
budget for direct costs of up $275,000 for the 2-year period with no more than
$200,000 allowed in any single year.
-
See http://grants.nih.gov/grants/guide/pa-files/PAR-06-113.html
for FOA.
Sarcoidosis: Research into the Cause of Multi-organ Disease
and Clinical Strategies for Therapy (R01)
Program Announcment: PA-07-136
Participating Institutes-NHLBI/NIAID/NIAMS/NEI/NIDDK/NINDS/NINR/ORD/ORWH
Due Date: Standard Due Dates Apply
Expires March 6, 2009
-
Purpose:
The primary objective of this FOA is to stimulate research on the etiology and
management of sarcoidosis, a human disorder of granulomatous
inflammation. We encourage research that seeks to identify not only the
cause of sarcoidosis, but seeks related predisposing factors, such as genomic,
proteomic, metabolomic, lipidomic or glycomic factors related to the etiology
of sarcoidosis. Investigations might include how sarcoidosis perturbs the
innate and acquired immunity systems; affects multi-organs within the human
body; and impacts biobehavioral and psychosocial factors of the individual,
family, and community. This program solicits innovative,
multidisciplinary basic and clinical research of sarcoidosis involving the
respiratory tract and other frequently involved organs, especially those of so-
called critical involvement (heart, eyes, liver, and neurologic system) with
the intent of accelerating progress in the discovery of the cause of
sarcoidosis and its diagnosis, prevention, and treatment. This program
also encourages methodologies and instruments that determine disease burden.
-
Mechanism of Support:
This FOA will utilize the R01 award mechanism.
-
Budget and Project Period:
total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-136.html
for FOA.
Research on the Cognitive Sequelae of Parkinson's Disease
(R01)
Program Announcement: PA-07-198
Participating Institutes-NINDS/NIA/NINR
Due Date: Standard Due Dates Apply
Expires November 6, 2008- R01
Expires January 8, 2009- R21, R03
-
Purpose:
Under this Funding Opportunity Announcement (FOA), the National Institute of
Neurological Disorders and Stroke (NINDS), the National Institute on Aging
(NIA), and the National Institute of Nursing Research (NINR) invite research
grant applications that address the underlying neurobiological mechanisms
associated with the cognitive impairment in Parkinson's disease (PD), that
address the development of clinical interventions and therapeutics for
cognitive impairment in PD, or that promote improved clinical diagnosis or
treatment of cognitive impairment in PD. A goal of this FOA is to begin a
process where basic and clinical scientists from various disciplines can
overcome barriers to cross-disciplinary and biobehavioral research and examine
all aspects of cognition in the context of the diagnosis and treatment of
Parkinson's disease.
-
Mechanism of Support:
This funding opportunity uses the R01 mechanism.
-
Budget and Project Period:
Total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See
http://grants.nih.gov/grants/guide/pa-files/PA-07-198.html
for R01 FOA.
-
See
http://grants.nih.gov/grants/guide/pa-files/PA-06-195.html
for R21 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-06-194.html
for R03 FOA.
In vivo Cancer Imaging Exploratory/Developmental
Grants (R21)
Program Announcement: PA-06-371
Participating Institute-NCI
Due Date: Standard Due Dates Apply
Expires May 8, 2009
-
Purpose:
The Cancer Imaging Program (CIP) of the Division of Cancer Treatment and
Diagnosis (DCTD) solicits exploratory/developmental (R21) applications that
articulate high risk and/or high impact research focused on in vivo cancer
imaging for detection, diagnosis, and monitoring of response to therapy.
Topics considered responsive to this Funding Opportunity Announcement (FOA)
will cover the entire spectrum of in vivo cancer imaging research, from basic
discovery of new cancer imaging agents and technologies, through pre-clinical
testing and validation, to the early feasibility testing of those novel agents
and technologies in small clinical trials.
-
Mechanism of Support:
This FOA utilizes the R21 grant mechanism only.
-
Budget and Project Period:
The total project period for an application submitted in response to this FOA
may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year
period, with no more than $200,000 in direct costs allowed in any single year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-06-371.html
for FOA.
Non-Invasive Methods for Diagnosis and Progression of
Diabetes, Kidney, Urological, Hematological and Digestive Diseases (R01)
Program Announcement: PA-07-025
Participating Institute-NCI
Due Date: Standard Due Dates Apply
Expires March 6, 2009
-
Purpose:
This Funding Opportunity Announcement (FOA) is a call for the application of
imaging and other non- or minimally-invasive technologies to detect,
characterize, diagnose, identify persons with predisposition to, or monitor
treatment of diseases of interest to the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), National Institutes of Health
(NIH). Also needed are new, robust surrogate markers for clinical trial
endpoints, and new ways to characterize normal and pathological tissues in
vivo. Diseases of interest include type 1 and 2 diabetes, obesity, and
kidney, liver, urologic, hematologic, digestive, endocrine, and metabolic
diseases and their complications. Applicable techniques include molecular
imaging and functional imaging approaches, imaging methods with high spatial,
chemical or time resolution, and new spectroscopic or sensor array technologies
for monitoring metabolic or physiological events.
-
Mechanism of Support:
This FOA will utilize the R01 award mechanism.
-
Budget and Project Period:
Total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-025.html
for FOA.
Exploratory Studies in Cancer Detection, Diagnosis,
and Prognosis (R21)
Program Announcement: PA-08-267
Participating Institute-NCI
Due Date: Standard Due Dates Apply
Expires September 8, 2012
-
Purpose:
The major goal of this initiative is to promote the initial evaluation of new
molecular or cellular characteristics of pre-malignant cells or tumors or the
development of assays that will be useful for cancer detection, diagnosis,
and/or prognosis. New biomarkers and laboratory assays are needed for cancer
screening and risk assessment, for pathologic characterization of malignant
tumors and assessment of disease prognosis, and for prediction and measurement
of response to treatments, particularly with novel therapeutic or
chemopreventive agents. Investigators are encouraged to pursue new clinical
insights and to consider the full array of potentially informative biological
characteristics of tumor cells and tissues. The investigator should provide a
strong rationale for proposing that a particular biomarker or assay has the
potential to address a significant clinical problem.
-
Mechanism of support:
This FOA utilizes the Exploratory/Developmental grant R21 mechanism.
-
Budget and Project Period:
The total project period for an application may not exceed 2 years. Direct
costs are limited to $275,000 over an R21 2-year period, with no more than
$200,000 in direct costs allowed in any single year.
-
Please see http://grants.nih.gov/grants/guide/pa-files/PA-06-299.html
for FOA.
Phased Innovation Research in Cancer Prognosis and
Prediction (R21/R33)
Program Announcement: PA-06-434
Participating Institute-NCI
Due Date: Standard Due Dates Apply
Expires May 8, 2009
-
Purpose:
This Funding Opportunity Announcement (FOA) is intended to accelerate the
translation of new discoveries into clinical practice by enabling investigators
to apply new diagnostic strategies to clinical problems. The desired outcome
will be studies with sufficient statistical power using efficient assay
techniques that are conclusive enough to support the initiation of larger
clinical trials designed to influence practice recommendations or to pursue
U.S. Food and Drug Administration (FDA) approval of a new device or analytic
reagent.
-
Mechanism of Support:
This FOA will utilize the NIH Phased Innovation (combined R21 [Phase I,
Exploratory]/R33 [Phase II, Developmental]) grant mechanism.
-
Budget and Project Period: The total project period may not
exceed 5 years. Direct costs are limited to $275,000 over an initial R21 2-year
period, with no more than $200,000 in direct costs allowed in any single year.
There are no direct cost limits on the R33 phase. However, there are
special instructions for applications requesting more than $500,000 (direct
costs) per year. Please see
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html
for complete description of policy and requirements.
-
Please see http://grants.nih.gov/grants/guide/pa-files/PA-06-434.html
for FOA.
Development, Application, and Evaluation of Prediction
Models for Cancer Risk and Prognosis (R01)
Program Announcement: PA-07-021
Participating Institute-NCI
Due Date: Standard Due Dates Apply
Expires January 8, 2010
-
Purpose:
The purpose of this Funding Opportunity Announcement (FOA) is to encourage
clinicians, epidemiologists, geneticists, statisticians, and translational
researchers working in the field of cancer control and prevention to impro96+ve
existing models for cancer risk and prognosis by developing innovative research
projects that use existing data; develop new models for cancer risk and
prognosis; and validate new models and evaluate their utility in research and
clinic settings. Applications that are focused on the identification and
characterization of prognostic/diagnostic markers are NOT responsive to this
FOA. Investigators should address two major challenges in model development,
which are: integrating diverse types of data (e.g., clinical, demographic,
pathologic, environmental, epidemiologic, outcomes, and genetic data from
varied data marts or warehouses); and ensuring adequate validation (i.e., using
multiple separate populations to define sensitivity, specificity, and positive
and negative predictive values).
-
Mechanism of Support:
This funding opportunity uses the R01 mechanism.
-
Budget and Project Period:
Total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-021.html
for R01 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-022.html
for R21 FOA.
Research on Mild and/or Unilateral Hearing Loss (R01)
Program Announcement: PA-07-038
Participating Institutes-NIDCD/NCBDDD
Due Date: Standard Due Dates Apply
Expires November 6, 2009
-
Purpose:
This Funding Opportunity Announcement (FOA) solicits R01 applications to
further our understanding of mild and unilateral hearing loss in infants and
young children. This includes research on prevention, better diagnostic
methods, and treatments for these forms of hearing loss that are often
overlooked or minimized. Children with milder forms of hearing loss (e.g., <
40 dB HL) in one or both ears or any degree of hearing loss in one ear can
experience difficulties in the areas of speech, language, behavior, academic,
and other aspects of development.
-
Mechanism of Support:
This FOA will utilize the R01 grant mechanism.
-
Budget and Project Period:
The total project may not exceed 5 years.
-
See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html-Special
Instructions for Applications requesting $500,000 (direct costs) or more per
year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-038.html
for RO1 FOA.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-07-037.html
for R21 FOA.
Pilot and Feasibility Clinical Research Grants in Diabetes,
Endocrine and Metabolic Diseases (R21)
Program Announcement: PA-06-387
Participating Institutes-NIDDK
Due Date: Standard Due Dates Apply
Expires May 8, 2009
-
Purpose:
The goal of this initiative is to encourage clinical research toward developing
new therapies for diabetes, endocrine and genetic metabolic diseases. The
Pilot and Feasibility Clinical Research Grants Program is designed to
support short-term clinical studies to help stimulate the translation of
promising research developments from the laboratory into clinical practice in
diabetes, endocrine diseases and genetic metabolic diseases including cystic
fibrosis. The short-term studies should focus on research questions that
are likely to have high clinical impact. They can include testing a new
prevention strategy, a new intervention, or unique combinations of therapies.
-
Mechanism of Support:
This FOA uses the NIH exploratory/developmental grant (R21) award mechanism.
-
Budget and Project Period:
The total project period may not exceed 2 years. Direct costs are limited to
$275,000 over the two years of the R21 award, with no more than $200,000 in
direct costs allowed in any single year.
-
See http://grants.nih.gov/grants/guide/pa-files/PA-06-387.html
for R21 FOA.
NIDCD Patient-Oriented
Research Grant (R01)
Program Announcement: PA-07-095
Participating Institute-NIDCD
Due Date: Standard Due Dates Apply
Expires May 8, 2009
Mitochondria in Cancer
Epidemiology, Detection, Diagnosis and Prognosis (R01)
Program
Announcement: PA-08-143
Participating Institutes-NCI
Due Date: Standard Due Dates Apply
Expires May 8, 2011
-
Purpose: The puropose of this
solicitation is to develop and validate new mitochondrial-related biomarkers
for cancer early detection, diagnosis, prognosis, risk assessment, and response
to preventive and ameliorative treatments. This FOA will stimulate research on
either mutations in mtDNA and/or mitochondrial proteome analysis, for
identification of additional indicators of tumor development and
-
Mechanism of Support: This FOA will
utilize the Research Project grant (R01) aware mechanism.
-
Budget and Project Period: The
total project may not exceed 5 years.
-
-
-
NIDCD Research Grants for
Translating Basic Research into Clinical Tools for Human Health (R01)
Program Announcement: PAR-08-017
Participating Institutes- National Institute on Deafness and Other
Communication Disorders (NIDCD
Due Date: June 17, 2009
Expires October 14, 2010
-
Purpose: The NIDCD is encouraging
applications which translate basic research findings into clinical tools for
better human health in the NIDCD mission areas of hearing, balance, smell,
taste, voice, speech and language. The intent of this Funding Opportunity
Announcement (FOA) is to provide a new avenue for basic scientists, clinicians
and clinical scientists to jointly initiate and conduct translational research
projects
-
Mechanism of Support: This FOA will
utilize the Research Project grant (R01) aware mechanism.
-
Budget and Project Period: The
total project may not exceed 5 years.
-
-
-
Predictive Multiscale Models of
the Physiome in Health and Disease (R01)
Program Announcement: PAR-08-023
Participating Institutes-NIBIB, NCI, NHLBI, NIA, NIAMS, NIDCD, NIDA, NIEHS,
NIGMS, NIMH, NINDS, NLM
Due Date: January 14, 2009
Expires September 16, 2010
-
Purpose: The goal of this
solicitation is to move the field of biomedical computational modeling forward
through the development of more realistic and predictive models of health and
disease. Specifically this FOA solicits the development of predictive
multiscale models of health and disease states that must include higher scales
of the physiome. The specific objectives are to develop multiscale models that
are physiologically mechanistic and biomedically relevant, to bring together
modeling and biomedical expertise to collaborate on building models, to
validate and test models with standard datasets, and to develop models that can
be explicitly shared with other modelers.
-
Mechanism of Support: This FOA will
utilize the Research Project grant (R01) aware mechanism.
-
Budget and Project Period: The
total project may not exceed 5 years.
-
-
Biomarkers of Infection-Associated
Cancers (R01)
Program Announcement: PA-08-156
Participating Institutes- NCI/NIDCR
Due Date: Standard Due Dates Apply
Expires May 8, 2011
-
Purpose: This funding opportunity
announcement (FOA), issued by the National Cancer Institute (NCI) and the
National Institute of Dental and Craniofacial Research (NIDCR), of the National
Institutes of Health (NIH), encourages the submission of Research Project Grant
(R01) applications from institutions and organizations that propose to identify
biomarkers for cancers where the etiology of the disease is attributed to
infectious agents.
-
Mechanism of Support: This FOA will
utilize the Research Project grant (R01) award mechanism.
-
Budget and Project Period: The
total project may not exceed 5 years.
-
-
-
Transdisciplinary Research on
Fatigue and Fatigability in Aging (R01)
Program Announcement: PA-08-161
Participating Institutes- NIA/NCI/NIDDK/NINR/ODS/ORWH
Due Date: Standard Due Dates Apply
Expires May 8, 2011
-
Purpose: The purpose of this
funding opportunity announcement (FOA) is to encourage submission of research
grant applications on fatigue and fatigability in aging. This FOA is intended
to promote research studies employing transdisciplinary approaches that could
lead to increased understanding of mechanisms contributing to, assessment of,
or potential interventions for, increased fatigue or fatigability in older
persons. Animal models and humans are appropriate for study under this FOA.
-
Mechanism of Support: This FOA will
utilize the Research Project grant (R01) award mechanism.
-
Budget and Project Period: The
total project may not exceed 5 years.
-
-
-
Investigational Nutrigenetic
Studies for Cancer Prevention (R01)
Program Announcement: PA-08-220 |
Participating Institutes-NCI/NINR/NIH
Due Date: Standard Due Dates Apply
Expires: September 8, 2011
-
Purpose: The overarching goal is to
examine whether genetic variants can predict individual response to dietary
components that alter cancer processes and modify individual susceptibly to
cancer. These studies will allow for personalization of cancer preventive
dietary strategies to reduce cancer risk in genetically susceptible
individuals.
-
Mechanism of Support: This FOA uses
the Research Project R01 Grant Award mechanism.
-
Budget and Project Period: The
total project may not exceed 5 years.
-
-
-
Etiology, Prevention, and
Treatment of Hepatocellular Carcinoma (R01)
Program Announcement: PA-08-243
Participating Institutes-NCI/NIDDK/NIAAA
Due Date: Standard Due Dates Apply-R01, R21
Due Date: January 28, 2009-P01
Expires: September 8, 2011
-
Purpose: With this Funding
Opportunity Announcement (FOA), the National Cancer Institute (NCI), the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and
the National Institute on Alcohol Abuse and Alcoholism (NIAAA) encourage grant
applications that: (a) address the etiology and etiologic mechanisms of
hepatocellular carcinoma (HCC); (b) propose development of animal models for
HCC; (c) propose novel approaches to prevent HCC malignancy; (d) propose
therapeutic or diagnostic tools for reliable prognostic indicators for HCC;
and/or (e) develop therapeutic approaches to minimize morbidity and mortality
associated with HCC in humans.
-
Mechanism of Support:
This FOA uses the Research Project R01 Grant Award mechanism.
-
Budget and Project Period: The
total project may not exceed 5 years.
-
-
-
-